Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Total accounts payable and accrued expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Liabilities Accounts Payable, Current Accounts payable Accounts Receivable Collection Period Accounts Receivable Collection Period Period of payments from customers Accounts Receivable, Net, Current Accounts receivable, net Accretion Expense Accretion of debt discount and loan costs Accrual to payment cycle period. Accrual To Payment Cycle Period Accrual to payment cycle period Accrued acquisition consideration. Accrued Acquisition Consideration Accrued acquisition consideration Estimates for rebates, administrative fee arrangements, reimbursements, and similar payments to wholesalers and other distributors. Accrued Chargebacks Accrued chargebacks Accrued costs to run clinical trials for portfolio product or product candidates. Accrued Clinical Trial Costs Accrued clinical trial costs Accrued Employee Benefits, Current Accrued compensation and benefits Accrued legal current. Accrued Legal Current Accrued legal costs Accrued costs to manufacture our products. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Manufacturing Costs Current Accrued manufacturing costs Accrued Marketing Costs, Current Accrued rebates Accrued estimates on account of billing adjustments, shelf stock adjustments, promotional payments, or other similar allowances affecting the licensed product. Accrued Price Adjustments Accrued price adjustments Accrued returns. Accrued Returns Accrued returns Accrued Royalties, Current Accrued royalties Accrued costs for the sales and marketing of our products and product candidates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Sales And Marketing Costs Current Accrued sales and marketing costs Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Adjustments to Additional Paid in Capital, Warrant Issued Issuance of warrants Allocated Share-based Compensation Expense Stock-based compensation expense Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization of intangible assets Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Securities excluded from computation of diluted earnings per share Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Award Type [Axis] Award Type [Axis] Basis Of Presentation [Line Items] Basis of Presentation [Line Items] Basis Of Presentation [Line Items] Basis Of Presentation [Table] Basis Of Presentation [Table] Basis Of Presentation [Table] BELBUCA (buprenorphine) buccal film for Chronic Pain. BELBUCA is a partial mu-opioid agonist and a treatment indicated for the management of pain severe enough to require daily, around the clock, long-term opioid treatment for which alternative treatment options are inadequate. Belbuca [Member] Belbuca [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Business Acquisition, Pro Forma Earnings Per Share, Basic Basic Business Acquisition, Pro Forma Earnings Per Share, Diluted Diluted Business Acquisition, Pro Forma Information [Table Text Block] Summary of Proforma Impact of Acquisition Business Acquisition Pro Forma Net Income Loss Per Share [Abstract] Business Acquisition Pro Forma Net Income Loss Per Share [Abstract] Pro forma net loss per common share Business Acquisition, Pro Forma Net Income (Loss) Net loss Business Acquisition, Pro Forma Revenue Revenue Business Combination [Abstract] Business Combination [Abstract] Business Combination [Abstract] Business Combination, Bargain Purchase, Gain Recognized, Amount Bargain purchase gain Bargain purchase gain Business Combination, Consideration Transferred Total asset purchase price Business Combination, Consideration Transferred [Abstract] Asset purchase price: Business Combination Disclosure [Text Block] Business Combination and Asset Acquisitions: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Estimated fair value of assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment BELBUCA®-related manufacturing equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Current BELBUCA® product inventory and work-in process Business combination recognized identifiable assets acquired and liabilities assumed license and distribution rights. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed License And Distribution Rights License and distribution rights intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Amount attributable to assets acquired Business Combinations [Abstract] Business Combinations [Abstract] Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized Recognized net product sales and earnings Business Combinations Policy [Policy Text Block] Reacquisition of BELBUCA Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of year Cash Cash and Cash Equivalents, Period Increase (Decrease) Cash generated Net change in cash and cash equivalents Class of Stock [Domain] Class of Stock [Domain] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Shares of common stock Clinical Trials Full Enrollment [Member] Clinical Trials Full Enrollment [Member] Clinical Trials Full Enrollment [Member] Clinical Trials One [Member] Clinical Trials One [Member] Clinical Trials One [Member] Clinical Trials Two [Member] Clinical Trials Two [Member] Clinical Trials Two [Member] Collegium license and development agreement. Collegium License And Development Agreement [Member] Collegium License and Development Agreement [Member] Commitments and Contingencies Commitments and contingencies (Notes 11 and 14) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies: Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common Stock, par value Common Stock, Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Common Stock, Shares, Outstanding Common Stock, shares outstanding Common Stock, Value, Issued Common Stock, $.001 par value; 75,000,000 shares authorized; 55,341,463 and 54,133,511 shares issued; 55,325,972 and 54,118,020 shares outstanding at March 31, 2017 and December 31, 2016, respectively. Computer Equipment [Member] Computer Equipment and Software [Member] Consolidation, Policy [Policy Text Block] Principles of consolidation Contracts Revenue Contract revenues Convertible Preferred Stock [Member] Series A Non-Voting Convertible Preferred Stock [Member] Cost of Revenue Cost of sales Cost of Sales, Policy [Policy Text Block] Cost of Sales CRG [Member] CRG Servicing LLC Agreement [Member] CRG [Member] CRG servicing LLC. CRG Servicing LLC [Member] CRG [Member] CRG warrants. CRG Warrants [Member] CRG Warrants [Member] Current Fiscal Year End Date Current Fiscal Year End Date Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Note Payable (MidCap Loan) Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Additional interest rate Long-term Debt, Gross Total maturities Debt instrument interest only payment term. Debt Instrument Interest Only Payment Term Loan agreement interest only term Debt instrument interest only payment term threshold. Debt Instrument Interest Only Payment Term Threshold Loan agreement interest only term threshold Debt Instrument, Interest Rate, Effective Percentage Effective interest on borrowings Debt instrument interest rate stated interest only period percentage. Debt Instrument Interest Rate Stated Interest Only Period Percentage Interest on borrowings, interest only period percentage Debt Instrument, Interest Rate, Stated Percentage Interest on borrowings Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt instrument prepayment fee after year five. Debt Instrument Prepayment Fee After Year Five Prepayment fee after Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Loan agreement term Deferred Income Tax Expense (Benefit) Deferred income taxes Deferred loan costs expensed. Deferred Loan Costs Expensed Deferred loan costs expensed Deferred Revenue, Current Deferred revenue, current Deferred Revenue, Noncurrent Deferred revenue, long-term Deferred Revenue, Refund Payments Deferred revenue refund payment Deferred Revenue, Revenue Recognized Milestone payment upon regulatory approval deferred for future revenue recognition Depreciation Depreciation Description of royalty payment. Description Of Royalty Payment Royalty payment description Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Effect of dilutive securities: Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic Basic income (loss) per common share Basic income (loss) per share: Earnings Per Share, Basic [Abstract] Basic Basic: Earnings Per Share, Diluted Diluted income (loss) per common share Diluted income (loss) per share: Earnings Per Share, Diluted [Abstract] Diluted Diluted: Earnings Per Share [Text Block] Earnings per Common Share Employee [Member] Employee [Member] Employees [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee service share based compensation non vested awards compensation cost to be recognized year Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Year Unrecognized compensation cost related to non-vested share-based compensation awards granted year Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation cost related to non-vested share-based compensation awards granted Endo agreement. Endo Agreement [Member] Endo Agreement [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Overview Policy [Text Block] Entity Overview [Policy Text Block] Overview Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Execution term of license agreement. Execution Term Of License Agreement Execution term of license agreement Executive Officer [Member] Executive Officer [Member] Extractive Industries [Abstract] Extractive Industries [Abstract] Fair Value of Assets Acquired Fair value of bargain purchase price of BELBUCA acquisition Final payment fees percentage. Final Payment Fees Percentage Final payment fee rate Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Remaining Amortization Period Amortization of intangible asset General and Administrative Expense Selling, general and administrative Goodwill Goodwill Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Idle equipment. Idle Equipment [Member] Idle Equipment [Member] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (loss) Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Expense (Benefit) Income tax benefit Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses, net of effect of acquisition Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Inventories Inventories, net of effect of acquisition Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Intangible Assets Disclosure [Text Block] Other license agreements and acquired product rights: Intangible Assets, Net (Excluding Goodwill) Other intangible assets, net Interest Expense Interest expense, net Interest Expense [Member] Interest Expense [Member] Interest Paid Cash paid for interest Inventory allowances recorded. Inventory Allowances Recorded Inventory allowances recorded Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventory Inventory, Finished Goods, Net of Reserves Finished goods Inventory, Net Inventory Total inventories Inventory, Policy [Policy Text Block] Inventory Inventory, Raw Materials and Supplies, Net of Reserves Raw materials & supplies Inventory, Work in Process, Net of Reserves Work-in-process Leasehold Improvements [Member] Leasehold Improvements [Member] Legal Entity [Axis] Legal Entity [Axis] Liabilities Total liabilities Liabilities and Equity Total liabilities and stockholders' equity (deficit) Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: License agreement acquisition. License Agreement Acquisition Disclosure [Text Block] License Obligations: License And Development Agreement [Text Block] License And Development Agreement [Text Block] License and Development Agreements License And Development Agreement Textual [Abstract] License And Development Agreement Textual [Abstract] License And Development Agreement Textual [Abstract] license and distribution rights. license And Distribution Rights BELBUCA®license and distribution rights intangible License and distribution rights. License And Distribution Rights [Member] License and Distribution Rights [Member] License and supply agreement term. License And Supply Agreement Term Term of the agreement License termination effective date. License Termination Effective Date License termination effective date Long-term Line of Credit Borrowings outstanding Line of credit facility additional borrowing capacity upon contingent milestone achievement. Line Of Credit Facility Additional Borrowing Capacity Upon Contingent Milestone Achievement Additional borrowing capacity upon milestone achievement Line of Credit Facility, Current Borrowing Capacity Secured loan facility Line of Credit Facility, Expiration Date Agreement maturity date Line of credit facility second draw borrowing capacity upon contingent milestone achievement. Line Of Credit Facility Second Draw Borrowing Capacity Upon Contingent Milestone Achievement Second draw borrowing capacity upon milestone achievement Significant financing sources and revenue generated during period and managements plans. Liquidity And Managements Plan Disclosure [Text Block] Liquidity and Management's Plans Liquidity and managements plans. Liquidity And Managements Plans [Abstract] Liquidity And Managements Plans [Abstract] Long-term Debt Total CRG obligation Long-term Debt, Maturities, Repayments of Principal in Year Five 2021 Long-term Debt, Maturities, Repayments of Principal in Year Four 2020 Long term debt maturities repayments of principal in year six. Long Term Debt Maturities Repayments Of Principal In Year Six 2022 Long-term Debt, Maturities, Repayments of Principal in Year Three 2019 Long-term Debt, Maturities, Repayments of Principal in Year Two 2018 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year 2017 Long-term Debt [Text Block] Term Loan Agreement (CRG) Notes Payable, Noncurrent Notes payable, less current maturities, net Machinery and Equipment [Member] Machinery and Equipment [Member] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Maximum [Member] Maximum [Member] MidCap Financial Trust [Member] Mid Cap Financial Trust [Member] Mid Cap Financial Trust [Member] Milestone payment received. Milestone Payment Received Milestone payment received Milestone payments. Milestone Payments Milestone payments Milestones. Milestones [Member] Milestones [Member] Minimum [Member] Minimum [Member] Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash flows from financing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash flows from investing activities Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash flows from operating activities Net Income (Loss) Attributable to Parent Net income Net income (loss) attributable to common stockholders Net income (loss) Net Income (Loss) Attributable to Parent, Diluted Net income (loss), diluted, Total Net Income (Loss) Available to Common Stockholders, Basic Net income (loss) New Accounting Pronouncements, Policy [Policy Text Block] Recent accounting pronouncements Noncash Investing and Financing Items [Abstract] Non-cash Financing and Investing Activities: Non refundable payment received. Non Refundable Payment Received Non-refundable payment received Number Of Clinical Trials Number Of Clinical Trials Number of clinical trials Number of largest wholesale customers. Number of Largest Wholesale Customers Number of large wholesalers Number of warrants type to purchase common stock. Number Of Warrants Type To Purchase Common Stock Number of warrants type issued Offered Period for Sales Return Prior to Expiration Offered Period for Sales Return Prior to Expiration Offered period for sales return prior to expiration Offered Period for Sales Return Subsequent to Expiration Offered Period for Sales Return Subsequent to Expiration Offered period for sales return subsequent to expiration Office Equipment [Member] Office Furniture and Equipment [Member] Operating Expenses Total Expenses: Operating Expenses [Abstract] Expenses: Operating Income (Loss) Income (loss) from operations Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Organization, basis of presentation and summary of significant policies Other Accrued Liabilities, Current Accrued other Other Liabilities, Noncurrent Other long-term liabilities Other license agreements and acquired product rights. Other License Agreements And Acquired Product Rights [Line Items] Other License Agreements And Acquired Product Rights [Line Items] Other License Agreements And Acquired Product Rights [Table] Other License Agreements And Acquired Product Rights [Table] Other License Agreements And Acquired Product Rights [Table] Other Nonoperating Income (Expense) Other expense, net Others. Others [Member] Others [Member] Patent extension year end. Patent Extension Year End Patent extension ending period Patent extension year start. Patent Extension Year Start Patent extension starting period Payables and Accruals [Abstract] Payables and Accruals [Abstract] Payments of Financing Costs Payment of deferred financing fees Payments receivable on achievement of potential sales milestones. Payments Receivable On Achievement Of Potential Sales Milestones Payment receivable on achievement of potential sales milestones Payments receivable on patent milestone. Payments Receivable On Patent Milestone Payment receivable related to patent milestone Payments receivable upon first sales. Payments Receivable Upon First Sales Payment receivable upon first commercial sale Payments to Acquire Businesses, Net of Cash Acquired Deferred cash consideration to Endo Payments to Acquire Property, Plant, and Equipment Purchase of equipment Percentage of accruals accounted by wholesalers. Percentage of Accruals accounted By Wholesalers Percentage of accruals accounted by three large wholesalers Percentage of vesting. Percentage Of Vesting Percentage of vesting Performance based vesting. Performance Based Vesting [Member] Performance-Based [Member] Potential milestone payment receivable intellectual property. Potential Milestone Payment Receivable Intellectual Property Potential milestone payments on intellectual property rights Potential Milestone Payment Receivable Regulatory Approval Potential Milestone Payment Receivable Regulatory Approval Potential milestone payment receivable upon regulatory approval Potential Milestone Payment Received Clinical Development Potential Milestone Payment Received Clinical Development Potential milestone payment received, clinical development Potential cash or stock payment upon NDA filing and acceptance. Potential Payments Upon Filing And Acceptance Potential payments upon filing and acceptance Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value Preferred Stock, Shares Authorized Preferred Stock, shares authorized Preferred Stock, Shares Outstanding Preferred Stock, shares outstanding Preferred Stock, Value, Issued Preferred Stock, $.001 par value; 5,000,000 shares authorized; 2,093,155 shares of Series A Non-Voting Convertible Preferred Stock outstanding at both March 31, 2017 and December 31, 2016, respectively. Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepayment period of outstanding principal and accrued unpaid interest. Prepayment Period Of Outstanding Principal And Accrued Unpaid Interest Prepayment period of outstanding principal and accrued unpaid interest Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Proceeds from Lines of Credit Net proceeds in aggregate amount Proceeds from (Repurchase of) Equity Equity financing costs Proceeds from Secured Notes Payable Proceeds from notes payable Proceeds from Stock Options Exercised Proceeds from exercise of stock options Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Property, Plant and Equipment, Gross Property, plant & equipment, gross Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Net Property and equipment, net Total property, plant & equipment, net Property, Plant and Equipment [Table Text Block] Summarized Category of Fixed Assets Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Useful Life Useful life of equipment Range [Axis] Range [Axis] Range [Domain] Range [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Remaining line of credit after deducting loan origination cost broker and other fees. Remaining Line Of Credit After Deducting Loan Origination Cost Broker And Other Fees Remainder of borrowings Repayments of Notes Payable Payment of notes payable Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Expense Research and development Research and Development Expense [Member] Research and Development [Member] Amount of revenue earned as a result of reimbursement from research and development arrangements. Research And Development Reimbursements Research and development reimbursements Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings [Member] Accumulated Deficit [Member] Revenue Recognition, Deferred Revenue [Policy Text Block] Deferred revenue Revenue Recognition, Milestone Method [Line Items] Revenue Recognition, Milestone Method [Line Items] Revenue Recognition, Milestone Method [Table] Revenue Recognition, Milestone Method [Table] Revenue Recognition, Policy [Policy Text Block] Revenue recognition Revenues Total Revenues: Revenues [Abstract] Revenues: Royalty payment description. Royalty Payment Description Royalty payment, term Royalty Revenue Product royalty revenues Sales Discounts In Percentages. Sales Discounts Percentage Discount for prompt payment Sales Returns Goods Period Sales Returns Goods Period Sales return maximum duration Sales Revenue, Goods, Net Product sales Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Summary of Components of Accounts Payable and Accrued Liabilities Schedule of Assumptions Used [Table Text Block] Weighted Average for Key Assumptions Used in Determining Fair Value of Warrants Granted Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Reconciliation of Numerators and Denominators of Basic and Diluted Loss Per Share Computations Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of Allocated Stock-based Compensation Expense Schedule of future maturities of debt obligation table. Schedule Of Future Maturities Of Debt Obligation [Table Text Block] Future Maturities of CRG Obligation Schedule of Inventory, Current [Table Text Block] Summary of Inventories Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Summary of Asset Purchase Price and Estimated Values of Assets Acquired and Liabilities Assumed Schedule of Share-based Compensation, Activity [Table Text Block] Summary of Total Outstanding Options and Warrants Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Summary of Restricted Stock Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Stock Option Activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Weighted Average for Key Assumptions Used in Determining Fair Value of Options Granted Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of Warrant Activity Secured Loan Facility [Member] Secured Loan Facility [Member] Secured Loan Facility [Member] Geographical [Domain] Geographical [Domain] Selling, General and Administrative Expenses [Member] Selling, General and Administrative [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Share-based Compensation Stock-based compensation expense Share-based Compensation, Allocation and Classification in Financial Statements [Abstract] Share-based Compensation, Allocation and Classification in Financial Statements [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period of shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of Restricted Shares, Forfeitures Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Fair Market Value Per RSU, Forfeitures Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of equity instruments awarded in period Number of Shares, Granted Share based compensation arrangement by share based payment award equity instruments other than options grants in period fair value. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value Fair market value of RSUs granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Fair Market Value Per RSU, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Restricted Shares, Outstanding at end of period Number of Restricted Shares, Outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Fair Market Value Per RSU, Outstanding at end of period Weighted Average Fair Market Value Per RSU, Outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Number of Restricted Shares, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Fair Market Value Per RSU, Vested Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Weighted average expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Warrants exercised, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Warrants forfeitures, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Warrants granted, Number of Shares Share based compensation arrangement by share based payment award non option equity instruments outstanding aggregate intrinsic value. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value Warrants outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Warrants outstanding at end of period, Number of Shares Warrants outstanding at beginning of period, Number of Shares Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Warrants outstanding at end of period, Weighted Average Exercise Price Per Share Warrants outstanding at beginning of period, Weighted Average Exercise Price Per Share Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price exercised. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Exercised Warrants exercised, Weighted Average Exercise Price Per Share Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price forfeitures. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Forfeitures Warrants forfeitures, Weighted Average Exercise Price Per Share Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price granted. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Granted Warrants granted, Weighted Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Stock option exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of Shares, Forfeitures Share based compensation arrangement by share based payment award options granted in period fair value. Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Fair Value Fair market value of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of Shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Aggregate Intrinsic Value, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding at end of period Aggregate Intrinsic Value, Outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Shares, Outstanding at end of period Number of Shares, Outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Outstanding at end of period Weighted Average Exercise Price Per Share, Outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vesting period of options Share based compensation arrangement by share based payment award shares outstanding. Share Based Compensation Arrangement By Share Based Payment Award Shares Outstanding Options, RSUs and warrants to purchase Common Stock Equity Award [Domain] Equity Award [Domain] Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average Exercise Price Per Share, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Forfeitures Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Granted Share based compensation arrangements by share based payment award term of options granted. Share Based Compensation Arrangements By Share Based Payment Award Term Of Options Granted Term of options granted period Shares, Issued Ending Balance, shares Beginning Balance, shares Class of Stock [Axis] Class of Stock [Axis] Equity Components [Axis] Equity Components [Axis] Geographical [Axis] Geographical [Axis] Statement [Line Items] Statement [Line Items] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Stockholders' Equity Attributable to Parent Ending Balance Beginning Balance Stockholders' (deficit) equity Total stockholders' equity (deficit) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Restricted stock awards, shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of Shares, Exercised Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Restricted stock awards Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Stock-based compensation Termination agreement date. Termination Agreement Date Termination agreement date Text Block [Abstract] Text Block [Abstract] Time based vesting. Time Based Vesting [Member] Time-Based [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Trading Symbol Trading Symbol Tranche One [Member] Tranche One [Member] Tranche One [Member] Tranche Two [Member] Tranche Two [Member] Tranche Two [Member] Treasury Stock [Member] Treasury Stock [Member] Treasury Stock, Shares Treasury stock, shares Treasury Stock, Value Treasury stock, at cost, 15,491 shares TTY license and supply agreement. TTY License And Supply Agreement [Member] TTY License and Supply Agreement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums Unamortized discount and loan costs Upfront payment of research and development expenses. Upfront Payment Of Research And Development Expenses Upfront payment UNITED STATES U.S. [Member] Use of Estimates, Policy [Policy Text Block] Use of estimates in financial statements Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Warrant [Member] Warrants [Member] Warrants Not Settleable in Cash, Fair Value Disclosure Fair value of warrants, in connection with CRG term loan Weighted Average Number Diluted Shares Outstanding Adjustment Effect of dilutive options and warrants Weighted Average Number of Shares Outstanding, Diluted Diluted weighted average common stock shares outstanding: Diluted weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding Weighted average common stock shares outstanding: